GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients | NYU Langone Health

Go Back to All Clinical Trials

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-small Cell Lung Cancer (nsclc)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1)Patients with Stage III/IV NSCLC on treatment with anti-PD-1/PD-L1 (ICI)+/ -chemotherapy. 2) Patients who have measurable disease including a lesion that is amenable to injection. 3) Patients who are able and willing to undergo a pre-treatment and on-treatment biopsy.

You may not be eligible for this study if the following are true:

1) Patients with a history of severe hypersensitivity reaction to ICI. 2) Patients who require ongoing therapy with systemic immunosuppressive drugs including systemic corticosteroids. 3) Patients with a history of active autoimmune disease requiring treatment in the past 2 years.